Callan Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Callan Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-15,864	Closed	-$2.53M	–	191
2022 Q4	$2.53M	Buy	+15,864	New	+$2.33M	0.31%	49

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Callan Capital's JAZZ Position: Q1 2023 in Review

Callan Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2023, closing a stake of 15,864 shares — an estimated $2.53M sold.

Callan Capital first reported a position in JAZZ in Q4 2022 and held it in 1 quarter. The position peaked at $2.53M in Q4 2022. 471 funds tracked by Wall St. Rank hold JAZZ as of Q1 2023.

Callan Capital reported no remaining Jazz Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Callan Capital sold 15,864 Jazz Pharmaceuticals shares in Q1 2023, an estimated $2.53M.
Callan Capital first reported a position in Jazz Pharmaceuticals in Q4 2022 and held it in 1 quarter.
Callan Capital's Jazz Pharmaceuticals position peaked at $2.53M in Q4 2022.
471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2023.

Based on Callan Capital's 13F filing for Q1 2023, filed 9 May 2023.